Sepantronium Bromide

N/A

Report date: 2025/02/17 15:31:37
NMEFirst In Class

Base Information

Drug NameSepantronium Bromide
Drug Alias NameSepantronii bromidum塞托溴铵Bromuro de sepantronio溴塞派铵YM-155 +[7] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionMyc proto-oncogene protein inhibitorsBaculoviral IAP repeat-containing protein 5 inhibitors
TargetsMyc proto-oncogene proteinBaculoviral IAP repeat-containing protein 5
Therapy Area/IndicationsSolid tumoursLymphatic DiseasesProstatic Neoplasms +[12] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumCanada +[15] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesAstellas Pharma Inc
China Registration ClassN/A

Develop Information

Active CompaniesKesai Rui Biotechnology (Hangzhou) Co LtdCothera Bioscience IncKeruihua Biotechnology Co Ltd +[4] 
Inactive CompaniesAstellas Pharma Us IncNational Cancer InstituteAstellas Pharma Inc +[4] 
Active IndicationsLymphatic DiseasesProstatic NeoplasmsLymphoma, Large B-Cell, Diffuse +[6] 
Inactive IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungLung Neoplasms +[6] 

Other Information

ATC CodeN/A
Related LinksDrugBankKEGG